MNG517
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R25 | — | — | 0.861 |
| 2 | R309 | — | — | 0.837 |
| 3 | SRR5088864 | — | — | 0.818 |
| 4 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.813 |
| 5 | SRR8518345 | — | E | 0.806 |
| 6 | BS_74FS6GMW | ATRT | — | 0.800 |
| 7 | C3N-02434 | — | cohortSQ2 | 0.799 |
| 8 | C3L-03965 | — | cohortSQ2 | 0.799 |
| 9 | MDT-AP-0426 | Med | Medulloblastoma | 0.795 |
| 10 | C3N-01074 | — | cohortA3 | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.436 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.435 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.366 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.339 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.305 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.225 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.205 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.185 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.179 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.172 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.171 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.163 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.152 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.119 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.113 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.105 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.098 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.088 | Inavolisib | — uncovered |
| HYPOXIA | 0.077 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.073 | Inavolisib | — uncovered |